Najat Khan - 06 Feb 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
CEO and President, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
06 Feb 2026
Net transactions value
-$41,249
Form type
4
Filing time
10 Feb 2026, 18:18:29 UTC
Previous filing
29 Dec 2025
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat CEO and President, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 10 Feb 2026 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +1,673,546 +274% $0.000000 2,284,681 06 Feb 2026 Direct F1
transaction RXRX Class A Common Stock Award $0 +30,346 +1.3% $0.000000 2,315,027 06 Feb 2026 Direct F2
transaction RXRX Class A Common Stock Tax liability $41,249 -10,364 -0.45% $3.98 2,304,663 06 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter.
F2 This RSU vested immediately upon the grant date.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.